BioTrace Medical Announces Key Events Featuring Tempo Lead at TVT 2018

BioTrace Medical, Inc., the leader in innovative temporary pacing
technology, today announced the company’s key activities at the
Transcatheter Valve Therapies (TVT) structural heart disease summit,
which will take place June 20-22 at the Sheraton Grand Chicago.

The company’s Tempo® Temporary Pacing Lead will be featured
in a New Technology Forum discussion titled “Improved Temporary
Transvenous Pacers: The BioTrace Tempo Lead,” presented by Steven
Yakubov, M.D., System Chief, Advanced Structural Heart Disease at
Riverside Methodist Hospital/OhioHealth.

The discussion will highlight the performance and benefits of the Tempo
Lead with a review of U.S. clinical experience with the device including
an overview of recent data from a
multi-center U.S. retrospective study. That study further
demonstrated that the Tempo Lead is safe and effective for temporary
cardiac pacing, provides stable peri- and post-procedural pacing
support, and facilitates post-procedure ambulation. He will
also review select case studies, including Riverside
Methodist Hospital’s experience with the use of the Tempo Lead,
which demonstrated an average reduction in length of stay from 3.1 to
1.7 days.

In addition, results of a single-center retrospective study of 112
patients demonstrating the safety and efficacy of the Tempo Lead will be
presented by Daniel S. Menees, M.D., of the Michigan Medicine Cardiology
Clinic | Cardiovascular Center at the University of Michigan. Dr. Menees
notes that the Tempo Lead facilitated post-procedure ambulation with 90%
of patients with the lead left in post-procedure ambulating.

The Tempo Lead will also be discussed as a potential solution to
complications resulting from permanent pacemakers following TAVR as part
of a presentation by Tamim Nazif, M.D., of NewYork-Presbyterian/Columbia
University Medical Center.

Details of presentations and events at TVT 2018 featuring the BioTrace
Tempo Lead are below (all times are Central Time):

TVT Hot Topics: TAVR IThursday, June
21Session 2: Significant Procedural Complications After TAVRIncidence,
Predictors and Consequences of New LBBB and New Permanent Pacemakers
After TAVR10:10 a.m.; Chicago Ballroom X

TVT New Technology Forum: TAVR IThursday,
June 21TAVR Accessories, Part 3: Pacemakers and
ValvuloplastyImproved Temporary Transvenous Pacers: The
BioTrace Tempo Lead11:00 a.m.; Sheraton Ballroom II-III

TVT Moderated Poster SessionThursday,
June 21Post-TAVR Utilization of a Novel Active-Fixation
Temporary Pacing Lead11:00 a.m.; Promenade, Ballroom Level,
4th Floor

About BioTrace Medical’s Tempo® Temporary
Pacing Lead

BioTrace Medical’s Tempo Lead is designed for secure and stable cardiac
pacing with the goal of reducing complications and allowing patients to
ambulate sooner after procedures such as TAVR. The Tempo Lead was
cleared by the Food and Drug Administration (FDA) in October 2016 for
use in all temporary pacing applications including: TAVR, reversible
symptomatic bradycardia support, and interventional procedures such as
alcohol septal ablations, pacemaker infections/extractions, and
generator changes. The Tempo Lead is the only active fixation temporary
pacing lead available in the U.S. Its unique design, which includes a
novel active fixation mechanism, bipolar electrodes, and a soft tip,
mitigates the risks of dislodgment and perforation, which are common
complications associated with conventional temporary pacing leads.

Results from a multi-center
retrospective analysis of 224 U.S. interventional cardiac procedures
including transcatheter aortic valve replacement (TAVR), confirm the
Tempo Lead is safe and effective for temporary cardiac pacing, provides
stable peri- and post-procedural pacing support, and facilitates
post-procedure ambulation.

About BioTrace Medical

BioTrace Medical, Inc., a private venture-backed company based in Menlo
Park, Calif., is dedicated to reinventing temporary pacing to improve
patient outcomes and reduce hospital costs. For more information, visit www.biotracemedical.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180618005425/en/